
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Because families will call on their child's pediatrician to interpret the results of expanded neonatal screening, it is important to consider the implications of these programs.






